Lantern Pharma (LTRN) Stock Statistics & Valuation Metrics

Lantern Pharma has a market cap or net worth of $47.99M. The enterprise value is $18.32M.

Lantern Pharma has 10,784,725 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lantern Pharma’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is 0.52%.

The current PE Ratio of Lantern Pharma is ―. Lantern Pharma’s PEG ratio is ―.

In the last 12 months, Lantern Pharma had revenue of 0.00 and earned -20.78B in profits. Earnings per share was -1.93K.

In the last 12 months, operating cash flow was -17.87M and capital expenditures -7.27K, giving a free cash flow of -17.87M billion.

Lantern Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Lantern Pharma upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).

Lantern Pharma as a current ratio of <0.01, with Debt / Equity ratio of 1.16%

In the past 12 months, Lantern Pharma has paid 0.00 in taxes.

Lantern Pharma EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.52.

Lantern Pharma has $15.90M in cash and marketable securities with $145.04K in debt, giving a net cash position of -$15.76M billion.

Gross margin is -2.09%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Lantern Pharma is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy